Hinge Health, Inc. (HNGE) is a publicly traded company in the Healthcare — Medical - Healthcare Information Services industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
Is Hinge Health, Inc. stock overvalued or undervalued in 2026?
Hinge Health, Inc. (HNGE) trades at 86.8× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $39 (-65 %).
Kaplio overview: Hinge Health, Inc.
Market cap $9B · 52 weeks $31 – $115 (0 % below the high) · P/E 86.8× · 2027 expected P/E 38.2× · Dividend none · Next earnings November 2, 2026 · expected EPS $0.57 · Closing price, Oct 28 · accounts published Aug 4.
- Valuation: P/E 86.8× (expensive).
- Business: ROIC 26 % (solid).
- Balance sheet: Net debt/EBITDA 0.4× (solid).
- Earnings: 5 of 6 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $39 (-65 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 4 of 4 pass
- R&D / Revenue 62.6 %, passes.
- Gross margin 79.8 %, passes.
- ROIC 26.3 %, passes.
- Net debt / EBITDA 0.4×, passes.
Against its peers (reference peers) — Hinge Health, Inc.: P/E 86.8×; EV/EBITDA 87.1×; ROIC 26.3 %; $9.0B. Smith & Nephew plc (P/E 19.6×; EV/EBITDA 9.4×; ROIC 8.8 %; $12.7B), HealthEquity, Inc. (P/E 36.6×; EV/EBITDA 18.3×; ROIC 8.6 %; $8.4B), BrightSpring Health Services, Inc. Common Stock (P/E 43.9×; EV/EBITDA 21.3×; ROIC 8.9 %; $11.7B).
Profitability
| Return on Equity | 30.25% |
| Return on Invested Capital | 26.29% |
| Return on Assets | 13.18% |
| Gross Margin | 84.52% |
| Operating Margin | 13.01% |
| Net Margin | 15.15% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 1.34 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.70 |
Price Performance
| 1 month | +21.08% |
| 3 months | +54.30% |
| Year-to-date | +148.18% |
| 1 year | +132.42% |
Related companies: SNN · TEM · BTSG · HQY · DOCS · WAY · HTFL · PRVA
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of HNGE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks